What is the recommended oral hydralazine dose for an adult patient?

Oral Hydralazine Dosing for Adults

For chronic heart failure with reduced ejection fraction (HFrEF), start hydralazine at 25-50 mg three or four times daily, titrating up to a maximum of 300 mg daily in divided doses, typically combined with isosorbide dinitrate. 1, 2

Standard Dosing Regimens

Heart Failure (Primary Indication)

The evidence-based dosing for heart failure comes from landmark trials:

• Initial dose: 25-50 mg three or four times daily
• Target dose: 75 mg three times daily (225 mg/day total)
• Maximum dose: 300 mg daily in divided doses
• Fixed-dose combination: Start with 37.5 mg hydralazine/20 mg isosorbide dinitrate three times daily, titrating to 75 mg hydralazine/40 mg isosorbide dinitrate three times daily 1, 2

Key point: Hydralazine should be combined with isosorbide dinitrate for heart failure treatment, as this combination demonstrated mortality reduction (NNT=43 for mortality reduction, 7% relative risk reduction) 1. This combination is particularly beneficial for self-identified African American patients with HFrEF already on optimal therapy 3, 4.

Hypertension (Alternative Indication)

For chronic hypertension management when other agents are unsuitable:

• Initial dose: 10 mg four times daily for the first 2-4 days
• Maintenance dose: 25 mg four times daily for the remainder of the first week
• Titration: Increase to 50 mg four times daily from the second week onward
• Maximum dose: 300 mg daily 5

Important caveat: Hydralazine is not a first-line agent for hypertension. Modern guidelines prioritize ACE inhibitors, ARBs, calcium channel blockers, and thiazide diuretics 6.

Dosing Frequency Considerations

Hydralazine requires multiple daily doses due to its pharmacokinetic profile:

• Twice-daily dosing: Acceptable for both rapid and slow acetylators when using conventional formulations 7
• Once-daily dosing: Unsatisfactory with conventional formulations, as the hypotensive effect wanes at 24 hours, particularly in rapid acetylators 7
• Three to four times daily: Optimal for sustained effect, especially in heart failure 1, 2

Acetylator Status Impact

NAT2 genotype significantly affects hydralazine metabolism 8:

• Slow acetylators (NAT2 poor metabolizers): D50 = 0.87 mg/kg daily
• Fast acetylators (NAT2 rapid metabolizers): D50 = 1.68 mg/kg daily 9

Slow acetylators achieve greater blood pressure reduction at lower doses but have increased risk of drug-induced lupus with prolonged use 8. However, routine genotyping is not required for dose initiation—start with standard doses and titrate based on clinical response.

Pediatric Dosing

For children (off-label use):

• Initial dose: 0.75 mg/kg/day divided into four doses
• Maximum dose: 7.5 mg/kg/day or 200 mg/day, whichever is lower
• Titration: Increase gradually over 3-4 weeks 5

Critical Prescribing Considerations

Mandatory Combination Therapy

Hydralazine must be combined with a beta-blocker and loop diuretic when used as a direct vasodilator to counteract reflex tachycardia, increased sympathetic tone, and sodium/fluid retention 6. This is non-negotiable for safety.

Not for Acute Use

Oral hydralazine is inappropriate for hypertensive emergencies due to unpredictable response and prolonged duration of action (2-4 hours) 10, 11, 12, 11, 12, 13. For acute severe hypertension, IV formulations or other agents are preferred.

Monitoring Requirements

• Complete blood counts and ANA titers: Before starting and periodically during therapy, even if asymptomatic 5
• Watch for: Arthralgia, fever, chest pain, peripheral neuritis (paresthesias, numbness, tingling)
• Consider pyridoxine supplementation if peripheral neuritis develops 5

Drug-Food Interaction

Administration with food increases plasma levels—maintain consistency in timing relative to meals 5.

Common Pitfalls to Avoid

1. Using hydralazine as monotherapy for hypertension: Always combine with beta-blocker and diuretic
2. Once-daily dosing: Ineffective for sustained blood pressure control
3. Forgetting the isosorbide dinitrate: In heart failure, the combination is what provides mortality benefit
4. Using for acute hypertensive crisis: Oral hydralazine has no role in emergencies
5. Ignoring acetylator status implications: While not requiring routine testing, be aware that slow acetylators need closer monitoring for lupus-like syndrome with chronic use